Secukinumab shows promise for psoriatic arthritis

A clinical trial of secukinumab, recently PBS-listed for plaque psoriasis, suggests it may also benefit patients with psoriatic arthritis.

The phase 3 double-blind randomised clinical trial (FUTURE2) compares three different doses of secukinumab with placebo, in nearly 400 patients at 76 centres across four continents, including Australia. The patients had active psoriatic arthritis, despite previous treatment.